



OPEN ACCESS

APPROVED BY

Michael Heinrich,
University College London, United Kingdom

*CORRESPONDENCE

Frontiers Editorial Office,
✉ research.integrity@frontiersin.org

RECEIVED 12 February 2025

ACCEPTED 12 February 2025

PUBLISHED 19 February 2025

CITATION

Frontiers Editorial Office (2025) Retraction:
Exploration of multiple signaling pathways
through which sodium tanshinone IIA sulfonate
attenuates pathologic remodeling
experimental infarction.

Front. Pharmacol. 16:1575629.

doi: 10.3389/fphar.2025.1575629

COPYRIGHT

© 2025 Frontiers Editorial Office. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License
\(CC BY\)](#). The use, distribution or reproduction in
other forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in this
journal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Retraction: Exploration of multiple signaling pathways through which sodium tanshinone IIA sulfonate attenuates pathologic remodeling experimental infarction

Frontiers Editorial Office*

A Retraction of the Original Research Article

[Exploration of multiple signaling pathways through which sodium
tanshinone IIA sulfonate attenuates pathologic remodeling experimental
infarction](#)

by Mao S, Vincent M, Chen M, Zhang M and Hinek A (2019) . *Front. Pharmacol.* 10:779. doi: 10.3389/fphar.2019.00779

The journal retracts the 12 July 2019 article cited above.

Following publication, concerns were raised regarding the integrity of the images in the published figures. Image duplication was identified between Figure 6B and 7B. Some panels of Figure 3C, 6B and 9B were also found to be published in other articles.

The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies. As a result, the data and conclusions of the article have been deemed unreliable, and the article has been retracted.

This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. Author MV agrees to this retraction. Authors SM, MC, MZ and AH did not respond to correspondence regarding this retraction.

Frontiers would like to thank the users on PubPeer for bringing the published article to our attention.